Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07031778

Topic Simvastatin for Bone Regeneration

The goal of this clinical trial is to evaluate the efficacy of topical application of simvastatin in bone regeneration in the maxillae, in the reduction of dimensional bone changes, using mandibular third molar surgery as a model and assessing bone healing at 12 weeks. We will also compare the two forms of intralveolar topical administration currently used to assess which is the best form of administration. The main questions it aims to answer are:

* Can the topical application of simvastatin, used as a preservation material, improve the variations with respect to bone dimensions and density that occur after tooth extraction. * Can topical application of SM improve soft tissue healing. * Does the topical application of SM produce changes with respect to postoperative variables of pain, inflammation or trismus. * What is the best vehicle for topical SM administration?

For this purpose, the investigators will randomly place 4 topical treatment options in the postextraction alveoli:

* SM in gel form * collagen sponge impregnated with saline solution containing 10 mg of SM * collagen sponge with placebo gel. All patients will undergo postoperative CBCT, which will be repeated at 12 weeks.

In addition, inflammation, trismus and pain variables will be measured preoperatively, at 24 hours, 3 and 7 days.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

UGranada

Granada, 18071, Spain

Location status: Recruiting

About this study

The study design is a double-blind randomized clinical trial (RCT). The study population consisted of patients referred to the Master's Degree in Oral Surgery and Implantology of the Faculty of Dentistry of the UGR (Granada) with an indication for surgical extraction of mandibular third molars.

A sample of 90 third molars will be used to establish a confidence level of 95% and a power of 90%. The sample will be divided into 3 groups of 30 each. Group I: 30 mandibular third molars in which gel with 1.2% simvastatin is used for healing. Group II: 30 mandibular third molars in which a collagen sponge impregnated with saline solution containing 10 mg of the active ingredient simvastatin is used for healing. Group III: 30 mandibular third molars in which a collagen sponge impregnated in gel without SM is used for healing.

SURGICAL PROCEDURE:

Extraction will be performed only of included mandibular third molars. For this purpose we will anesthetize the lower dental nerve, lingual nerve and buccal nerve using 4% articaine with epinephrine by means of the truncular technique.

The intervention will be performed by flap lifting, ostectomy with handpiece and round bur, or odontosection with turbine whenever the case requires it. The socket will be curetted and washed with physiological saline solution to ensure that no surgical debris remains. After this, we will proceed to place in the socket the combination of material chosen by randomization (simvastatin gel, gel without simvastatin, collagen sponge with simvastatin or only collagen sponge). Once the filling material has been placed, we will proceed to the primary closure of the wound with 3.0 silk. We will place a gauze with 0.20% chlorhexidine gel at the end of the extraction, for the patient to keep it for 30 minutes. We will indicate to the patient the appropriate postoperative care and we will prescribe 0.12% chlorhexidine mouthwash for rinsing after brushing. One week later, the patient will be seen to remove the suture.

Postoperative medication:

  • Antibiotic treatment: amoxicillin 750 mg 1 every 8 hours, for 7 days. In case of allergy to penicillin, the drug of choice will be clindamycin 300 mg 1 every 8 hours.
  • Analgesic and anti-inflammatory treatment: ibuprofen 400 mg 1 every 8 hours for two days, from the third day on demand. Rescue paracetamol 1 g.

VARIABLES TO BE STUDIED

Primary Variables:

The primary variable to be studied will be the dimensional changes

Secondary variables:

The secondary variables to be studied will be bone density measured in Hounsfield units , soft tissue healing, pain and analgesia, inflammation and trismus.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Anesthetic risk ASA I-II.
  • Patients with the adjacent tooth in the mouth (37 or 47).
  • Third molars with fully developed roots.
  • Mandibular third molars included or semi-included.
  • With indication for extraction.
  • Signed informed consent.

Exclusion criteria

  • Pregnant or lactating women.
  • Chronic smokers.
  • Patients with decompensated metabolic disease.
  • Patients with motor difficulties that prevent or hinder hygiene.
  • Patients who are using statins to treat hypercholesterolemia.
  • Patients under treatment with drugs that could affect the osseointegration process such as chemotherapy drugs, bisphosphonates, corticosteroids or immunosuppressants.
  • Patients with metabolic bone diseases or who have undergone radiotherapy in the last five years.

Treatment and study plan

simvastatin

Drug

Simvastatin gel with 1.2% simvastatin

Simvastatin 10 mg

Drug

sponge of collagen impregned in saline solution with 10 mg of simvastatin

Simvastatin Placebo

Drug

Collagen sponge impregned in simvastatin placebo gel without simvastatin

Primary outcomes

  1. Dimensional changes

    Time frame: From the time of extraction to when bone regeneration is supposed to be completed 12 weeks later.

    The primary variable to be studied will be the bone dimensional changes that occur after tooth extraction, both horizontally and vertically. These will be assessed by means of CBCT scans carried out immediately postoperatively (T0) and 12 weeks later (T1).

Secondary outcomes

  1. Bone density

    Time frame: Postextraction to the end of bone regeneration at 12 week latter

    Bone density measured in Hounsfield units on CBCT post-extraction and at 12 weeks

Study contacts

Contact information is provided by the study sponsor or research team.

Lopez-Andrade E Elena López-Andrade

CONTACT

[email protected]

+34656821779 ext. +34

Manzano-Moreno FJ Francisco Javier Manzano-Moreno

CONTACT

[email protected]

+34651606228 ext. +34

Sponsors and collaborators

Lead sponsor

Universidad de Granada

Other

Registry information

Official study title

Efficacy of Topical Application of Simvastatin in Bone Regeneration

Acronym: SM

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jun 22, 2025
Registry last updated
Jun 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.